Two biotech names on Josh Brown's Best Stocks list are making meaningful highs this summer
The article highlights biotech stocks Incyte (INCY) and Biogen (BIIB) on Josh Brown’s “Best Stocks” list, saying both are near summer highs. It cites INCY Q2 revenue of $1.67B and adjusted EPS $3.09, plus raised net sales guidance to $5.13B-$5.26B. For BIIB, it cites Q2 revenue $2.74B and adjusted EPS $3.60, plus FDA approval and Apellis acquisition.
How this was made
The 30-second read
Why it matters
INCY’s catalyst is a same-quarter earnings beat plus raised guidance and accelerating non-Jakafi growth, while BIIB’s catalyst is a Q2 mix shift toward its Growth Portfolio plus an FDA-approved at-home dosing option and acquisition synergy expectations.
Market read
Traders get concrete, quarter-specific catalysts (earnings, guidance, FDA approval, acquisition synergy expectations) plus actionable technical reference levels for breakout or stop monitoring.
What to watch
Acquisition integration and GAAP optics (deal costs) could reintroduce volatility; technical levels cited may not account for broader biotech risk-off moves.
Background
This is a CNBC segment highlighting two biotech names on Josh Brown’s “Best Stocks” list, pairing fundamental Q2 details with technical levels and risk management.
Ticker impact
Incyte reported Q2 results with adjusted EPS $3.09 vs $2.12 consensus, raised full-year net sales guidance, and the stock jumped over 10% to a 52-week high.
Near-term bias remains upward while price holds above the cited intermediate trend levels; a failure to reclaim the 52-week high would likely trigger consolidation.
The article provides specific, time-linked fundamentals (Q2 beat, guidance raise, product growth) and ties them to a same-day >10% move and technical levels traders can monitor.
Biogen’s Q2 report showed Growth Portfolio out-earning legacy MS, with FDA approval of an at-home dosing option and acquisition-related synergy expectations.
If BIIB closes above the article’s $218 breakout level, momentum traders may extend longs; otherwise, the stock may remain range-bound.
The text includes concrete earnings and FDA approval details, but the technical framing is more prescriptive than the article’s disclosure of new, incremental facts beyond the reported quarter.
Market effects
Reinforces biotech as a “HALO trade” where AI-driven efficiency narratives and non-legacy growth can re-rate winners.
Primarily US large-cap biotech sentiment; limited direct regional spillover described.
No explicit global policy or cross-border catalyst beyond FDA-related approval and US earnings/guidance.
Counterpoint
The article’s bullish setup may be vulnerable to profit-taking after a sharp earnings-driven run, especially if guidance relies on execution of newer pipeline assets.
Key entities
- companyIncyte
Reported Q2 results with adjusted EPS beat, raised full-year net sales guidance, and highlighted growth beyond Jakafi.
- companyBiogen
Reported Q2 results with Growth Portfolio outperformance, FDA approval for at-home dosing, and acquisition-related synergy expectations.
- companyVega Therapeutics
Acquired by Incyte during the quarter for $1.25 billion (as described in the article).
- companyApellis
Acquired by Biogen (as described in the article), adding eye and rare-disease drugs.
